Jonathan Chang
Leerink Partners | Healthcare
Jonathan Chang is an analyst from Leerink Partners specializing in the Healthcare sector. They are beginning to establish their track record, with 4 stock ratings so far. Their current stats show a success rate of 100.00% and an average return of 25.42%.
Jonathan Chang has only issued 4 ratings so far. While the sample size is small, their early calls show a success rate of 100.00% and an average return of 25.42%. Investors may find their initial activity in the Healthcare sector worth watching as they build a track record.
Recent Ratings Analysis
REPL
BuyOct 20, 2025
Target
$13.00
Current
$8.10
Performance
-9.50%
Jonathan Chang rated REPL as Outperform on Oct 20, 2025, setting a price target of 13. The stock has underperformed, dropping 9.50% despite the bullish target of 13.
ZLAB
BuyJun 30, 2025
Target
$75.00
Current
$29.15
Performance
-16.64%
On Jun 30, 2025, ZLAB was given a Outperform rating by Jonathan Chang, with a target price of 75. Despite the Buy call, shares fell from 29.15 to 29.15, challenging the optimistic stance.
GMAB
BuyFeb 13, 2025
Target
$27.00
Current
$30.13
Performance
44.02%
GMAB received a Outperform rating from Jonathan Chang on Feb 13, 2025, aiming for 27. Momentum has favored the Buy call, with shares climbing from 30.13 to 30.13, rewarding those who trusted the recommendation.
VINC
BuyOct 08, 2024
Target
$2.00
Current
$0.04
Performance
-99.51%
On Oct 08, 2024, Jonathan Chang published a Outperform outlook on VINC, with a target of 2. Market action contradicted the Buy thesis, as shares slipped to 0.04.
IMCR
BuyApr 29, 2024
Target
$74.00
Current
$33.57
Performance
-42.22%
Jonathan Chang on Apr 29, 2024 assigned IMCR a Outperform rating, with a price target of 74. The call has struggled to gain traction, with shares losing 42.22%.